Growth HormoneMetabolicFDA Approved

Tesamorelin

Also known as Egrifta

GHRH analog FDA-approved for HIV-associated lipodystrophy.

Overview

Tesamorelin is a stabilized 44-amino-acid GHRH analog approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Mechanism

GHRH receptor agonism → endogenous GH release.

Research areas

Visceral adiposity
HIV-associated lipodystrophy
Cognition

Related peptides

Semaglutide

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

View

Tirzepatide

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

View

Retatrutide

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

View